EXEL moved above its 50-day moving average on December 23, 2024 date and that indicates a change from a downward trend to an upward trend. In of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 281 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for EXEL moved out of overbought territory on December 02, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on December 17, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.244) is normal, around the industry mean (18.292). P/E Ratio (21.819) is within average values for comparable stocks, (87.498). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (1.756). EXEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.890) is also within normal values, averaging (260.038).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
TSL | 21.47 | 1.78 | +9.04% |
GraniteShares 1.25x Long Tsla Daily ETF | |||
JPEF | 68.64 | 0.70 | +1.03% |
JPMorgan Equity Focus ETF | |||
DGRO | 62.15 | 0.52 | +0.84% |
iShares Core Dividend Growth ETF | |||
SEIX | 23.88 | -0.02 | -0.06% |
Virtus Seix Senior Loan ETF | |||
FAZ | 6.10 | -0.21 | -3.33% |
Direxion Daily Financial Bear 3X ETF |
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.
Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
---|---|---|---|---|
EXEL | 100% | +1.02% | ||
SRPT - EXEL | 36% Loosely correlated | +1.03% | ||
ALNY - EXEL | 34% Loosely correlated | +0.41% | ||
TECH - EXEL | 33% Poorly correlated | +0.40% | ||
MRSN - EXEL | 32% Poorly correlated | +5.88% | ||
ORMP - EXEL | 32% Poorly correlated | N/A | ||
More |